首页 > 最新文献

Recent patents on biotechnology最新文献

英文 中文
Direct Organogenesis of Citrus Cultivars from Shoot Tip Nodal Segments. 柑橘栽培品种的芽尖节段直接器官发生。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.2174/1872208317666230417084141
Zekeria Yusuf, Mulugeta Desta, Wassu Mohammed

Background: Citrus cultivar improvement via conventional breeding strategies is impeded by factors related to its reproductive biology. The orange is a hybrid between pomelo (Citrus maxima) and mandarin (Citrus reticulata). Among various orange cultivars, Valencia oranges have a bit of bitter tang mixed in with their sweetness, as Navel oranges are, the most widely cultivated citrus species, quite sweeter, and also don't contain any seeds. Tangelo mandarin orange cultivar is a hybrid of C. reticulata × C. maxima or × C. paradisi.

Objective: The present study was undertaken to optimize the hormonal composition of the media with regard to plant growth regulators for in vitro propagation of sweet orange cultivars from nodal segment explants.

Methods: The nodal segment explants were collected from three citrus cultivars, Washington Navel, Valencia and Tangelo. Murashige and Skoog (MS) medium supplemented with sucrose and different concentrations of growth regulators was used for shoot proliferation and root induction, and the optimum medium composition was assessed. The patent for Citrus Tissue Culture was obtained from the Office of Research Affairs, Haramaya University.

Results: The results indicate that the highest shoot response was recorded for Washington's navel with maximum shoot proliferation rate (99.75%), shoot number per explant (1.76), shoot length (10.70 cm), leaf number per explants (3.54) after three weeks of culture. In all experiments, no growth was observed for the basal MS medium. Phytohormone combinations of IAA (1.2 mg/L) and kinetin (2.0 mg/L) were found to be the best for shoot proliferation. Among the cultivars, there were significant differences for the highest rooting rate (81.255), root number (2.22), and root length (2.95 cm) variables for Washington Navel. The lowest rooting rate (48.45%), root number (1.47) and root length (2.26 cm) were observed for Valencia. The highest rooting rate (84.90%), root number per microshoot (2.22) and root length (3.05 cm) was on MS medium supplemented with 1.5 mg/L NAA.

Conclusion: A comparison of different concentrations of IAA and NAA on root induction of microshoots from nodal segments of citrus cultivars demonstrated NAA was a more effective hormone than IAA.

背景:通过传统育种策略改良柑橘栽培品种受到其生殖生物学相关因素的阻碍。橙子是柚子(Citrus maxima)和柑橘(Citrus reticulata)的杂交种。在各种橙子栽培品种中,瓦伦西亚橙子的甜味中夹杂着一点苦味,而脐橙是栽培最广泛的柑橘品种,甜度较高,而且不含任何种子。柚子柑栽培品种是 C. reticulata × C. maxima 或 × C. paradisi 的杂交种:本研究旨在优化从节段外植体体外繁殖甜橙栽培品种的培养基中植物生长调节剂的激素组成:方法:从华盛顿脐橙、瓦伦西亚和丹桂三种柑橘栽培品种中采集节段外植体。使用添加了蔗糖和不同浓度生长调节剂的 Murashige 和 Skoog(MS)培养基进行芽增殖和根诱导,并评估了最佳培养基成分。柑橘组织培养的专利权由原谷大学研究事务办公室授予:结果表明,华盛顿脐橙的芽反应最高,培养三周后,芽增殖率(99.75%)、每个外植体的芽数(1.76)、芽长(10.70 厘米)和每个外植体的叶片数(3.54)均达到最高值。在所有实验中,基础 MS 培养基均未观察到生长。IAA(1.2 毫克/升)和松香素(2.0 毫克/升)的植物激素组合对嫩芽增殖效果最好。在各栽培品种中,华盛顿脐橙的最高生根率(81.255)、根数(2.22)和根长(2.95 厘米)变量存在显著差异。瓦伦西亚的生根率(48.45%)、根数(1.47)和根长(2.26 厘米)最低。在添加了 1.5 毫克/升 NAA 的 MS 培养基上,华盛顿脐橙的生根率(84.90%)、每小芽生根数(2.22)和根长(3.05 厘米)最高:比较了不同浓度的 IAA 和 NAA 对柑橘栽培品种节段小芽生根诱导的影响,结果表明 NAA 是比 IAA 更有效的激素。
{"title":"Direct Organogenesis of Citrus Cultivars from Shoot Tip Nodal Segments.","authors":"Zekeria Yusuf, Mulugeta Desta, Wassu Mohammed","doi":"10.2174/1872208317666230417084141","DOIUrl":"10.2174/1872208317666230417084141","url":null,"abstract":"<p><strong>Background: </strong>Citrus cultivar improvement via conventional breeding strategies is impeded by factors related to its reproductive biology. The orange is a hybrid between pomelo (<i>Citrus maxima</i>) and mandarin (<i>Citrus reticulata</i>). Among various orange cultivars, Valencia oranges have a bit of bitter tang mixed in with their sweetness, as Navel oranges are, the most widely cultivated citrus species, quite sweeter, and also don't contain any seeds. Tangelo mandarin orange cultivar is a hybrid of <i>C. reticulata × C. maxima</i> or <i>× C. paradisi</i>.</p><p><strong>Objective: </strong>The present study was undertaken to optimize the hormonal composition of the media with regard to plant growth regulators for <i>in vitro</i> propagation of sweet orange cultivars from nodal segment explants.</p><p><strong>Methods: </strong>The nodal segment explants were collected from three citrus cultivars, Washington Navel, Valencia and Tangelo. Murashige and Skoog (MS) medium supplemented with sucrose and different concentrations of growth regulators was used for shoot proliferation and root induction, and the optimum medium composition was assessed. The patent for Citrus Tissue Culture was obtained from the Office of Research Affairs, Haramaya University.</p><p><strong>Results: </strong>The results indicate that the highest shoot response was recorded for Washington's navel with maximum shoot proliferation rate (99.75%), shoot number per explant (1.76), shoot length (10.70 cm), leaf number per explants (3.54) after three weeks of culture. In all experiments, no growth was observed for the basal MS medium. Phytohormone combinations of IAA (1.2 mg/L) and kinetin (2.0 mg/L) were found to be the best for shoot proliferation. Among the cultivars, there were significant differences for the highest rooting rate (81.255), root number (2.22), and root length (2.95 cm) variables for Washington Navel. The lowest rooting rate (48.45%), root number (1.47) and root length (2.26 cm) were observed for Valencia. The highest rooting rate (84.90%), root number per microshoot (2.22) and root length (3.05 cm) was on MS medium supplemented with 1.5 mg/L NAA.</p><p><strong>Conclusion: </strong>A comparison of different concentrations of IAA and NAA on root induction of microshoots from nodal segments of citrus cultivars demonstrated NAA was a more effective hormone than IAA.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":"63-70"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9751820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Five Escherichia coli Strains to Achieve the Maximum Yield of a Recombinant Immunotoxin Consisting of an Antibody against VEGF Conjugated with MAP30 Toxin in a Benchtop Bioreactor. 五株大肠杆菌在BenchtopBioreactor中获得由与MAP30毒素结合的VEGF抗体组成的重组免疫毒素的最大产量的比较
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.2174/1872208317666230316111554
Mina Zarei, Mohammad Hossein Morowvat

Background: Cancer is among the leading causes of death worldwide, imposing high costs on the health systems of all societies. Extensive biological studies are required to discover appropriate therapies. Escherichia coli has long been regarded as one of the main biotechnological bio-factories to produce recombinant protein-based therapeutics. In the present study, five strains of E. coli were compared to achieve the maximum production of a previously designed recombinant immunotoxin-carrying MAP30 toxin against VEGF-overexpressed cancer cells in a benchtop bioreactor.

Methods: The recombinant immunotoxin coding gene sequence was extracted from the NCBI database. The host used to produce the recombinant immunotoxin were five E. coli strains of BL21 (DE3), DH5α, SHuffle®T7, XL1-Blue, and Rosetta-gamiTM (DE3). CaCl2 method was used for bacterial transformation. Bacterial growth measurements were performed using optical density measurements at 600 nm. The immunotoxin production was measured using SDS-PAGE analysis. The best-producing strain was cultivated in a 10-L benchtop stirred tank bioreactor. Recent patents on this field were also studied.

Results: The results demonstrated that the BL21 (DE3) strain had the highest expression of recombinant protein in comparison to other strains. Moreover, the cell growth of E. coli BL21 (DE3) and SHuffle®T7 strains before transformation in the LB medium, were significantly higher in comparison to other strains. Additionally, the transformation of Rosettagami was associated with decreased cell proliferation. The transformation of the XL1-Blue strain did not effect cell growth. Analysis of the growth kinetics demonstrated appropriate proliferation of the transformed BL21 (DE3) cells in the laboratory benchtop bioreactor.

Conclusions: Based on the results of this study, the BL21 (DE3) strain could be used as a suitable host for the production of the recombinant immunotoxin against VEGF in stirred tank bioreactor, which can be employed for the treatment of tumors. Yet, its precise mechanism must be explored in extensive studies.

癌症是世界范围内的主要死亡原因之一,给所有社会的卫生系统带来了高昂的成本。需要广泛的生物学研究来发现合适的治疗方法。大肠杆菌一直被认为是生产重组蛋白治疗药物的主要生物技术生物工厂之一。在本研究中,研究人员比较了5株大肠杆菌,以在台式生物反应器中最大限度地生产先前设计的携带免疫毒素的重组MAP30毒素,以对抗vegf过表达的癌细胞。从encbi数据库中提取重组免疫毒素编码基因序列。用于产生重组免疫毒素的宿主为BL21 (DE3)、DH5α、SHuffle®T7、XL1-Blue和Rosetta-gamiTM (DE3) 5种大肠杆菌。用cacl2法进行细菌转化。使用600 nm光密度测量进行细菌生长测量。采用SDS-PAGE分析测定免疫毒素的产生。在10- l台式搅拌槽生物反应器中培养出产量最高的菌株。结果表明,与其他菌株相比,BL21 (DE3)菌株的重组蛋白表达量最高。此外,大肠杆菌大肠杆菌21 (DE3)和SHuffle®T7在LB培养基中转化前的细胞生长显著高于其他菌株。此外,Rosetta-gami的转化与细胞增殖减少有关。XL1-Blue菌株的转化对细胞生长没有影响。生长动力学分析表明转化后的BL21 (DE3)细胞在实验室台式生物反应器中有适当的增殖。基于本研究结果,BL21 (DE3)菌株可作为在搅拌槽生物反应器中生产抗VEGF重组免疫毒素的合适宿主,用于肿瘤的治疗。然而,它的确切机制还有待于广泛的研究。基于本研究结果,BL21 (DE3)菌株可作为搅拌式生物反应器中生产抗VEGF重组免疫毒素的合适宿主,用于肿瘤的治疗。然而,它的确切机制还有待于广泛的研究。没有一个
{"title":"Comparison of Five Escherichia coli Strains to Achieve the Maximum Yield of a Recombinant Immunotoxin Consisting of an Antibody against VEGF Conjugated with MAP30 Toxin in a Benchtop Bioreactor.","authors":"Mina Zarei, Mohammad Hossein Morowvat","doi":"10.2174/1872208317666230316111554","DOIUrl":"10.2174/1872208317666230316111554","url":null,"abstract":"<p><strong>Background: </strong>Cancer is among the leading causes of death worldwide, imposing high costs on the health systems of all societies. Extensive biological studies are required to discover appropriate therapies. <i>Escherichia coli</i> has long been regarded as one of the main biotechnological bio-factories to produce recombinant protein-based therapeutics. In the present study, five strains of <i>E. coli</i> were compared to achieve the maximum production of a previously designed recombinant immunotoxin-carrying MAP30 toxin against VEGF-overexpressed cancer cells in a benchtop bioreactor.</p><p><strong>Methods: </strong>The recombinant immunotoxin coding gene sequence was extracted from the NCBI database. The host used to produce the recombinant immunotoxin were five <i>E. coli</i> strains of BL21 (DE3), DH5α, SHuffle<sup>®</sup>T7, XL1-Blue, and Rosetta-gami<sup>TM</sup> (DE3). CaCl<sub>2</sub> method was used for bacterial transformation. Bacterial growth measurements were performed using optical density measurements at 600 nm. The immunotoxin production was measured using SDS-PAGE analysis. The best-producing strain was cultivated in a 10-L benchtop stirred tank bioreactor. Recent patents on this field were also studied.</p><p><strong>Results: </strong>The results demonstrated that the BL21 (DE3) strain had the highest expression of recombinant protein in comparison to other strains. Moreover, the cell growth of <i>E. coli</i> BL21 (DE3) and SHuffle<sup>®</sup>T7 strains before transformation in the LB medium, were significantly higher in comparison to other strains. Additionally, the transformation of Rosettagami was associated with decreased cell proliferation. The transformation of the XL1-Blue strain did not effect cell growth. Analysis of the growth kinetics demonstrated appropriate proliferation of the transformed BL21 (DE3) cells in the laboratory benchtop bioreactor.</p><p><strong>Conclusions: </strong>Based on the results of this study, the BL21 (DE3) strain could be used as a suitable host for the production of the recombinant immunotoxin against VEGF in stirred tank bioreactor, which can be employed for the treatment of tumors. Yet, its precise mechanism must be explored in extensive studies.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":"52-62"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45511239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fundamental Uses of Peptides as a New Model in Both Treatment and Diagnosis. 多肽作为治疗和诊断新模式的基本用途
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.2174/1872208317666230512143508
Hend Okasha

An amino acid short chain is known as a peptide. Peptide bonds are the connections that hold the amino acids of a peptide together in a particular order. Characteristically, the shorter length of peptides helps to identify them from proteins. Different ways are used to classify peptides, including chain length, source of peptides, or their biological functions. The fact that peptides serve several purposes suggests that there is a foundation for improvement in peptide production and structure to enhance action. In addition, many patents on peptides for therapeutic and diagnostic approaches have been obtained. This review aims to give an overview of peptides used recently in treatment and diagnosis.

氨基酸短链被称为肽。肽键是将肽的氨基酸按特定顺序连接在一起的连接。从特征上讲,较短长度的肽有助于从蛋白质中识别它们。使用不同的方法对肽进行分类,包括链长、肽来源或其生物功能。肽具有多种用途这一事实表明,肽的生产和结构的改进有助于增强作用。这篇综述旨在概述近年来在治疗和诊断中使用的肽。
{"title":"Fundamental Uses of Peptides as a New Model in Both Treatment and Diagnosis.","authors":"Hend Okasha","doi":"10.2174/1872208317666230512143508","DOIUrl":"10.2174/1872208317666230512143508","url":null,"abstract":"<p><p>An amino acid short chain is known as a peptide. Peptide bonds are the connections that hold the amino acids of a peptide together in a particular order. Characteristically, the shorter length of peptides helps to identify them from proteins. Different ways are used to classify peptides, including chain length, source of peptides, or their biological functions. The fact that peptides serve several purposes suggests that there is a foundation for improvement in peptide production and structure to enhance action. In addition, many patents on peptides for therapeutic and diagnostic approaches have been obtained. This review aims to give an overview of peptides used recently in treatment and diagnosis.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":"110-127"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42728317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human DNA Mutations and their Impact on Genetic Disorders. 人类DNA突变及其对遗传疾病的影响。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.2174/0118722083255081231020055309
Safia Samir

DNA is a remarkably precise medium for copying and storing biological information. It serves as a design for cellular machinery that permits cells, organs, and even whole organisms to work. The fidelity of DNA replication results from the action of hundreds of genes involved in proofreading and damage repair. All human cells can acquire genetic changes in their DNA all over life. Genetic mutations are changes to the DNA sequence that happen during cell division when the cells make copies of themselves. Mutations in the DNA can cause genetic illnesses such as cancer, or they could help humans better adapt to their environment over time. The endogenous reactive metabolites, therapeutic medicines, and an excess of environmental mutagens, such as UV rays all continuously damage DNA, compromising its integrity. One or more chromosomal alterations and point mutations at a single site (monogenic mutation) including deletions, duplications, and inversions illustrate such DNA mutations. Genetic conditions can occur when an altered gene is inherited from parents, which increases the risk of developing that particular condition, or some gene alterations can happen randomly. Moreover, symptoms of genetic conditions depend on which gene has a mutation. There are many different diseases and conditions caused by mutations. Some of the most common genetic conditions are Alzheimer's disease, some cancers, cystic fibrosis, Down syndrome, and sickle cell disease. Interestingly, scientists find that DNA mutations are more common than formerly thought. This review outlines the main DNA mutations that occur along the human genome and their influence on human health. The subject of patents pertaining to DNA mutations and genetic disorders has been brought up.

DNA是一种非常精确的复制和存储生物信息的介质。它是细胞机械的设计,允许细胞、器官甚至整个生物体工作。DNA复制的保真度源于数百个参与校对和损伤修复的基因的作用。所有的人类细胞都可以在一生中获得DNA的基因变化。基因突变是指在细胞分裂过程中,当细胞复制自己时,DNA序列发生的变化。DNA突变可能会导致遗传疾病,如癌症,或者随着时间的推移,它们可以帮助人类更好地适应环境。内源性反应性代谢产物、治疗药物和过量的环境诱变剂,如紫外线,都会持续损害DNA,损害其完整性。单个位点的一个或多个染色体改变和点突变(单基因突变),包括缺失、重复和反转,说明了这种DNA突变。当基因从父母那里遗传时,可能会发生遗传疾病,这会增加患上这种特殊疾病的风险,或者一些基因改变可能随机发生。此外,遗传疾病的症状取决于哪个基因发生了突变。突变导致了许多不同的疾病和状况。一些最常见的遗传疾病是阿尔茨海默病、一些癌症、囊性纤维化、唐氏综合症和镰状细胞病。有趣的是,科学家们发现DNA突变比以前想象的更常见。这篇综述概述了人类基因组中发生的主要DNA突变及其对人类健康的影响。
{"title":"Human DNA Mutations and their Impact on Genetic Disorders.","authors":"Safia Samir","doi":"10.2174/0118722083255081231020055309","DOIUrl":"10.2174/0118722083255081231020055309","url":null,"abstract":"<p><p>DNA is a remarkably precise medium for copying and storing biological information. It serves as a design for cellular machinery that permits cells, organs, and even whole organisms to work. The fidelity of DNA replication results from the action of hundreds of genes involved in proofreading and damage repair. All human cells can acquire genetic changes in their DNA all over life. Genetic mutations are changes to the DNA sequence that happen during cell division when the cells make copies of themselves. Mutations in the DNA can cause genetic illnesses such as cancer, or they could help humans better adapt to their environment over time. The endogenous reactive metabolites, therapeutic medicines, and an excess of environmental mutagens, such as UV rays all continuously damage DNA, compromising its integrity. One or more chromosomal alterations and point mutations at a single site (monogenic mutation) including deletions, duplications, and inversions illustrate such DNA mutations. Genetic conditions can occur when an altered gene is inherited from parents, which increases the risk of developing that particular condition, or some gene alterations can happen randomly. Moreover, symptoms of genetic conditions depend on which gene has a mutation. There are many different diseases and conditions caused by mutations. Some of the most common genetic conditions are Alzheimer's disease, some cancers, cystic fibrosis, Down syndrome, and sickle cell disease. Interestingly, scientists find that DNA mutations are more common than formerly thought. This review outlines the main DNA mutations that occur along the human genome and their influence on human health. The subject of patents pertaining to DNA mutations and genetic disorders has been brought up.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":"288-315"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71485479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative Nanomaterials for Targeting Hypoxia to Improve Treatment for Triple-negative Breast Cancer. 靶向缺氧的创新纳米材料改善三阴性乳腺癌的治疗。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.2174/0118722083270521231027074157
Suman Kumar Ray, Sukhes Mukherjee

Triple-negative breast cancer (TNBC) is an aggressive breast cancer with a high rate of metastases, a short overall survival time, and a poor response to targeted therapy. Improving tumor hypoxia by lowering the oxygen consumption rate of breast tumor cells is a powerful strategy. A viable way to address this issue is to improve therapeutic efficacy by improving the effectiveness of radiation and overcoming drug resistance in TNBC treatment by controlling hypoxia in the tumor microenvironment. The failure of radiation and chemotherapy in TNBC is frequently caused by hypoxia. In TNBC therapy, novel nanomaterials are used for oxygen delivery or generation to affect the tumor microenvironment to improve the effects of ionizing radiation using nanoplatforms. One of the growing fields is novel nano-based drug delivery devices for hypoxic regions and hypoxia- inducible factor-1 (HIF1) targeted therapeutics. Biocompatible nanoparticles may be used in the treatment of TNBC patients in the clinic. Because of the rising market and competition, intellectual property rights (IPR), patents, and tactics may be critically considered. To better comprehend the current state of IPR and patents in cancer nanotechnology, this overview examines recent advances and sophisticated protection measures in this area.

三阴性乳腺癌(TNBC)是一种转移率高、总生存时间短、对靶向治疗反应差的侵袭性乳腺癌。通过降低乳腺肿瘤细胞的耗氧量来改善肿瘤缺氧是一种有效的策略。解决这一问题的可行途径是通过控制肿瘤微环境缺氧,提高放疗效果,克服TNBC治疗中的耐药,从而提高治疗效果。TNBC放化疗失败的原因多为缺氧。在TNBC治疗中,新型纳米材料被用于氧的输送或产生,以影响肿瘤微环境,从而利用纳米平台改善电离辐射的效果。其中一个日益增长的领域是用于缺氧区域和缺氧诱导因子-1 (HIF1)靶向治疗的新型纳米药物递送装置。生物相容性纳米颗粒可用于临床治疗TNBC患者。由于日益激烈的市场和竞争,知识产权(IPR)、专利和策略可能被批判性地考虑。为了更好地了解癌症纳米技术知识产权和专利的现状,本文概述了该领域的最新进展和复杂的保护措施。
{"title":"Innovative Nanomaterials for Targeting Hypoxia to Improve Treatment for Triple-negative Breast Cancer.","authors":"Suman Kumar Ray, Sukhes Mukherjee","doi":"10.2174/0118722083270521231027074157","DOIUrl":"10.2174/0118722083270521231027074157","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is an aggressive breast cancer with a high rate of metastases, a short overall survival time, and a poor response to targeted therapy. Improving tumor hypoxia by lowering the oxygen consumption rate of breast tumor cells is a powerful strategy. A viable way to address this issue is to improve therapeutic efficacy by improving the effectiveness of radiation and overcoming drug resistance in TNBC treatment by controlling hypoxia in the tumor microenvironment. The failure of radiation and chemotherapy in TNBC is frequently caused by hypoxia. In TNBC therapy, novel nanomaterials are used for oxygen delivery or generation to affect the tumor microenvironment to improve the effects of ionizing radiation using nanoplatforms. One of the growing fields is novel nano-based drug delivery devices for hypoxic regions and hypoxia- inducible factor-1 (HIF1) targeted therapeutics. Biocompatible nanoparticles may be used in the treatment of TNBC patients in the clinic. Because of the rising market and competition, intellectual property rights (IPR), patents, and tactics may be critically considered. To better comprehend the current state of IPR and patents in cancer nanotechnology, this overview examines recent advances and sophisticated protection measures in this area.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":"269-272"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92156318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Outline of the Immunogenic Potential of Progressing SARSCoV- 2 Vaccine Technologies among Children and Adolescents. 进展中的SARS-CoV-2疫苗技术在儿童和青少年中的免疫原性潜力概述
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.2174/1872208317666230612141930
Hytham Ghanem, Shehab Ghanem, Ehsan AlMutawa

Background: SARS-CoV-2, a highly dynamic beta-coronavirus, can afflict all age groups. Notably, over 16100 mortalities have been recorded among children as yet. In this regard, many vaccine projects are operational to assess immuno-potency among young cohorts. A bulk of reports have evidenced the efficacy of these immunization technologies in the elderly population, though the impact is yet to be determined among children.

Objectives: This review is envisioned to outline the current efficacy of contributing vaccine technologies and examine the dose-dependent impact of immunization regimens in lowering the risks of SARS-CoV-2 infections among children and adolescents. Furthermore, the current review exclusively estimated the vaccine impact at current doses.

Methods: A total of 52 research papers extracted from PubMed, Pubmed Central, Science Direct, Research Gate, Google Scholar and Semantic Scholar were screened along with an emphasis on patents. Inclusion criteria involved all published reports directly or indirectly linked to the contributing vaccine candidates that are operational among the young cohort. Unrelated research papers were excluded from the study. Key search terminologies included information on vaccine identifiers, such as name, type and clinical trial ID, and successively restricted to children and adolscents age groups.

Results: Several vaccine designs, such as mRNA-based vaccinations, viral vector vaccines, DNA vaccines, inactivated vaccines, recombinant vaccines, and protein-based immunizations, are being examined at various stages of clinical trials to gauge the effects on children and adolescents. With reference to the published reports, the mRNA 1273 (1610 GMT; 6-10 yrs, 1401 GMT; 12-15 yrs), BNT162b2 (1407 GMT; 6 months- <2 yrs, 1535 GMT; 2-4 yrs, 4583 GMT; 5-11 yrs, 1239.5 GMT; 12-15 yrs) and Ad5 nCoV (1037.5 GMT; 6-17 yrs) offered relatively high neutralization titers with sharp seroconversion rates compared to MVC-COV1901 (648.5 GMT; 12-17 yrs) and ZyCoV-D (133.49 GMT; 12-17 yrs), which produced modest immune responses.

Conclusion: Currently, the WHO is analyzing emerging evidence to issue an emergency use list of vaccines for vaccinating children and adolescents.

SARS-CoV-2是一种高度动态的乙型冠状病毒,可影响所有年龄组。值得注意的是,截至目前,儿童死亡人数已超过16100人。在这方面,许多疫苗项目正在运作,以评估年轻人群体的免疫效力。大量报告证明了这些免疫技术对老年人的有效性,但对儿童的影响尚待确定。本综述旨在概述现有疫苗技术的有效性,并研究免疫方案在降低儿童和青少年感染SARS-CoV-2风险方面的剂量依赖性影响。此外,目前的审查只估计了当前剂量下疫苗的影响。从PubMed、PubMed Central、ScienceDirect、research Gate、谷歌Scholar、Semantic Scholar等网站共筛选了52篇研究论文。纳入标准涉及所有与在年轻队列中起作用的候选疫苗直接或间接相关的已发表报告。不相关的研究论文被排除在研究之外。关键搜索术语包括疫苗标识符信息,如名称、类型和临床试验ID,并先后限制在儿童和青少年年龄组。几种疫苗设计,如基于mrna的疫苗接种、病毒载体疫苗、DNA疫苗、灭活疫苗、重组疫苗和基于蛋白质的免疫接种,正在临床试验的不同阶段进行审查,以评估对儿童和青少年的影响。参考已发表的报告,mRNA 1273(格林威治标准时间1610;6-10年,1401 GMT;12-15年),BNT162b2(格林尼治标准时间1407;6个月- <2年,1535 GMT;2-4年,4583 GMT;5-11年,1239.5 GMT;12-15岁)和Ad5 nCoV(格林威治标准时间1037.5;6-17岁)提供相对较高的中和滴度,与MVC-COV1901 (648.5 GMT;12-17岁)和ZyCoV-D (133.49 GMT;目前,世卫组织正在分析新出现的证据,以发布一份用于为儿童和青少年接种疫苗的紧急使用清单。
{"title":"An Outline of the Immunogenic Potential of Progressing SARSCoV- 2 Vaccine Technologies among Children and Adolescents.","authors":"Hytham Ghanem, Shehab Ghanem, Ehsan AlMutawa","doi":"10.2174/1872208317666230612141930","DOIUrl":"10.2174/1872208317666230612141930","url":null,"abstract":"<p><strong>Background: </strong>SARS-CoV-2, a highly dynamic beta-coronavirus, can afflict all age groups. Notably, over 16100 mortalities have been recorded among children as yet. In this regard, many vaccine projects are operational to assess immuno-potency among young cohorts. A bulk of reports have evidenced the efficacy of these immunization technologies in the elderly population, though the impact is yet to be determined among children.</p><p><strong>Objectives: </strong>This review is envisioned to outline the current efficacy of contributing vaccine technologies and examine the dose-dependent impact of immunization regimens in lowering the risks of SARS-CoV-2 infections among children and adolescents. Furthermore, the current review exclusively estimated the vaccine impact at current doses.</p><p><strong>Methods: </strong>A total of 52 research papers extracted from PubMed, Pubmed Central, Science Direct, Research Gate, Google Scholar and Semantic Scholar were screened along with an emphasis on patents. Inclusion criteria involved all published reports directly or indirectly linked to the contributing vaccine candidates that are operational among the young cohort. Unrelated research papers were excluded from the study. Key search terminologies included information on vaccine identifiers, such as name, type and clinical trial ID, and successively restricted to children and adolscents age groups.</p><p><strong>Results: </strong>Several vaccine designs, such as mRNA-based vaccinations, viral vector vaccines, DNA vaccines, inactivated vaccines, recombinant vaccines, and protein-based immunizations, are being examined at various stages of clinical trials to gauge the effects on children and adolescents. With reference to the published reports, the mRNA 1273 (1610 GMT; 6-10 yrs, 1401 GMT; 12-15 yrs), BNT162b2 (1407 GMT; 6 months- <2 yrs, 1535 GMT; 2-4 yrs, 4583 GMT; 5-11 yrs, 1239.5 GMT; 12-15 yrs) and Ad5 nCoV (1037.5 GMT; 6-17 yrs) offered relatively high neutralization titers with sharp seroconversion rates compared to MVC-COV1901 (648.5 GMT; 12-17 yrs) and ZyCoV-D (133.49 GMT; 12-17 yrs), which produced modest immune responses.</p><p><strong>Conclusion: </strong>Currently, the WHO is analyzing emerging evidence to issue an emergency use list of vaccines for vaccinating children and adolescents.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":"180-189"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46447225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intellectual Property Rights: Protection of Biotechnological Inventions in India. 知识产权:印度生物技术发明的保护
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.2174/1872208317666230612145600
Virendra Gomase, Kiran Kemkar, Vaishali Potnis

The current Intellectual Property Rights (IPR) framework supports the commercialization of seed improvement, monoculture, and the patent protection of novel plant varieties, microorganisms, and genetically modified animals. As a consequence, our rich biogenetic diversity is irreversibly dissipating. However, we need to figure out how to create a methodology for elective choices that will achieve harmony between the official Intellectual Property (IP) structure and maintainable biodiversity components. The majority of the biotechnology sector's programmes in India are managed by the Department of Biotechnology. It is under the Ministry of Science and Technology. Its goals are to provide services in the fields of study, infrastructure, human resource development, biotechnology popularisation, industry promotion, and establishment of centres of excellence. Implementation of practise biosafety regulations for genetically modified organisms, recombinant DNA products, and programmes is based on biotechnology for the good of society. This creates an information network for India's bioinformatics mission in the local, national, and worldwide scientific community.

目前的知识产权框架支持种子改良、单一栽培以及保护新植物品种、微生物和转基因动物的商业化。因此,我们丰富的生物遗传多样性正在不可逆转地消失。然而,我们需要弄清楚如何创建一种选择性选择的方法,以实现官方知识产权(IP)结构与可维持的生物多样性组成部分之间的和谐。印度生物技术部门的大多数方案是由生物技术部管理的。它隶属于科学技术部。它的目标是在研究、基础设施、人力资源开发、生物技术普及、促进工业发展和建立卓越中心等领域提供服务。实施转基因生物、重组DNA产品和项目的生物安全法规是基于造福社会的生物技术。这为印度在地方、国家和世界科学界的生物信息学使命创建了一个信息网络。
{"title":"Intellectual Property Rights: Protection of Biotechnological Inventions in India.","authors":"Virendra Gomase, Kiran Kemkar, Vaishali Potnis","doi":"10.2174/1872208317666230612145600","DOIUrl":"10.2174/1872208317666230612145600","url":null,"abstract":"<p><p>The current Intellectual Property Rights (IPR) framework supports the commercialization of seed improvement, monoculture, and the patent protection of novel plant varieties, microorganisms, and genetically modified animals. As a consequence, our rich biogenetic diversity is irreversibly dissipating. However, we need to figure out how to create a methodology for elective choices that will achieve harmony between the official Intellectual Property (IP) structure and maintainable biodiversity components. The majority of the biotechnology sector's programmes in India are managed by the Department of Biotechnology. It is under the Ministry of Science and Technology. Its goals are to provide services in the fields of study, infrastructure, human resource development, biotechnology popularisation, industry promotion, and establishment of centres of excellence. Implementation of practise biosafety regulations for genetically modified organisms, recombinant DNA products, and programmes is based on biotechnology for the good of society. This creates an information network for India's bioinformatics mission in the local, national, and worldwide scientific community.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":"128-143"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45906862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Technology Prospection of Ora-pro-Nóbis (Pereskia aculeata Mill.): A Non-conventional Food Plant. Ora-pro-Nóbis(Pereskia aculeata Mill.)的技术展望:一种非常规食用植物。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.2174/1872208317666230502101802
Kellen Miranda Sá, Igor Lima Soares, Marcos Venânces de Souza Leão, Maria Izabel Carneiro Ferreira, Patrícia Georgina Garcia do Nascimento, Claudilane Martins Pontes, Alane Maia da Hora, Lucas Pontes Leal, Maria Nilka de Oliveira, Mary Anne Medeiros Bandeira, Dorasilvia Ferreira Pontes

Background: The ora-pro-nóbis (Pereskia aculeata Mill.) is a plant from Brazilian biodiversity used for food and medicinal purposes. It has ample technological potential, however, it is still underutilized, being classified as a Non-Conventional Food Plant (PANC). Prospective studies in intellectual property banks make it possible to expand perspectives for scientific research, enhancing the generation of new products.

Objective: Evaluate the patents of products containing Pereskia aculeata Mill. for the areas of food and health in intellectual property databases.

Methods: The study was conducted through structured prospective investigation (collection, processing and analysis) in 4 patent databases: National Institute of Intellectual Property (INPI) - Brazil, United States Patent and Trademark Office, World Trade Organization Intellectual Property (WIPO) and Espacenet.

Results: The evaluation showed a reduced number of registered patents. In general, 8 patent applications were examined, of which 7 are directly associated with the species (and its derivatives) and 1 is related to a device specially designed for harvesting leaves/fruits and removing thorns. The focus of the patents was the use of the species in the food, pharmaceutical and biotechnological areas, with emphasis on the use of the leaves in the extraction of mucilage and proteins.

Conclusion: This study showed that Pereskia aculeata Mill. is a technologically promising plant, because of its nutritional and medicinal composition, and it is important to encourage innovation and the development of new products with the species.

背景:orra-pro-nóbis(Pereskia aculeata Mill.)是巴西生物多样性中的一种植物,用于食用和药用。它具有巨大的技术潜力,但仍未得到充分利用,被列为非常规食用植物(PANC)。知识产权库中的前瞻性研究可以拓展科学研究的前景,促进新产品的开发:评估知识产权数据库中含有 Pereskia aculeata Mill:本研究通过对 4 个专利数据库进行结构化前瞻性调查(收集、处理和分析)来进行:结果:评估显示,在巴西国家知识产权局(INPI)、美国专利商标局、世界贸易组织知识产权局(WIPO)和 Espacenet:评估结果表明,注册专利数量有所减少。总体而言,共审查了 8 项专利申请,其中 7 项与该物种(及其衍生物)直接相关,1 项与专门设计用于采摘叶片/果实和去除刺的装置有关。专利的重点是该物种在食品、制药和生物技术领域的应用,重点是利用叶片提取粘液和蛋白质:这项研究表明,Pereskia aculeata Mill.因其营养和药用成分而成为一种具有技术前景的植物,因此鼓励创新和开发该物种的新产品非常重要。
{"title":"Technology Prospection of Ora-pro-Nóbis (<i>Pereskia aculeata</i> Mill.): A Non-conventional Food Plant.","authors":"Kellen Miranda Sá, Igor Lima Soares, Marcos Venânces de Souza Leão, Maria Izabel Carneiro Ferreira, Patrícia Georgina Garcia do Nascimento, Claudilane Martins Pontes, Alane Maia da Hora, Lucas Pontes Leal, Maria Nilka de Oliveira, Mary Anne Medeiros Bandeira, Dorasilvia Ferreira Pontes","doi":"10.2174/1872208317666230502101802","DOIUrl":"10.2174/1872208317666230502101802","url":null,"abstract":"<p><strong>Background: </strong>The ora-pro-nóbis (<i>Pereskia aculeata</i> Mill.) is a plant from Brazilian biodiversity used for food and medicinal purposes. It has ample technological potential, however, it is still underutilized, being classified as a Non-Conventional Food Plant (PANC). Prospective studies in intellectual property banks make it possible to expand perspectives for scientific research, enhancing the generation of new products.</p><p><strong>Objective: </strong>Evaluate the patents of products containing <i>Pereskia aculeata</i> Mill. for the areas of food and health in intellectual property databases.</p><p><strong>Methods: </strong>The study was conducted through structured prospective investigation (collection, processing and analysis) in 4 patent databases: National Institute of Intellectual Property (INPI) - Brazil, United States Patent and Trademark Office, World Trade Organization Intellectual Property (WIPO) and Espacenet.</p><p><strong>Results: </strong>The evaluation showed a reduced number of registered patents. In general, 8 patent applications were examined, of which 7 are directly associated with the species (and its derivatives) and 1 is related to a device specially designed for harvesting leaves/fruits and removing thorns. The focus of the patents was the use of the species in the food, pharmaceutical and biotechnological areas, with emphasis on the use of the leaves in the extraction of mucilage and proteins.</p><p><strong>Conclusion: </strong>This study showed that <i>Pereskia aculeata</i> Mill. is a technologically promising plant, because of its nutritional and medicinal composition, and it is important to encourage innovation and the development of new products with the species.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":"144-151"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9397937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gonadotropic Activity of Pituitary Extract of African Catfish, Clarias gariepinus, in Mammals using Immature Wistar Rats as Models. 以未成熟Wistar大鼠为模型的非洲鲶鱼(Clarias gariepinus)垂体提取物在哺乳动物中的促性腺活性
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.2174/1872208317666230313153832
Simon Azubuike Ubah, Samson Eneojo Abalaka, Victory Clara Asibor, Ebenezer Kehinde Ogundana, Itodo Joy Iyojo, Oluwa Adikpe Agbonu, Philemon Kwinjoh Columbus, Kenneth Owoicho Abah, Christopher Ese Obudu, Oluwatobi Akefe Isaac, Prisca Adaoma Ezinwo

Background: The pituitary glands normally produce and stores gonadotropic hormones (GnH) that are responsible for ovulation and spermiation in animals. However, whether fish pituitary extracts can elicit same effects in treated animals need elucidation as a prelude to their practical usage in animals.

Objectives: The aim of this study was to investigate the oestrus-inducing potential of the pituitary gland extract of the Africa Catfish (Clarias gariepinus) in immature Wistar rats.

Methods: The experiment involved the use of 18 immature female Wistar rats and 10 male catfish brood stocks with the use of six Wistar rats per groups as follows: Group A had human chorionic gonadotropin (hCG) treatment. Group B had only normal saline treatment as the control whereas Group C had the C. gariepinus pituitary extract administration to induce oestrus with treatments occurring twice six hours apart in each group.

Results: There was an obvious expression of visible signs of heat and the presence of uterine horn oedema with significant (p < 0.05) increase in reproductive tract weight and uterine width and length. However, only progesterone levels increased significantly (p < 0.05) in the hCG and the C. gariepinus pituitary extract treated groups compared to other assayed hormones.

Conclusion: These results showed that C. gariepinus pituitary extract has the capacity to induce oestrus in Wistar rats because of its gonadotropic effects, which needs further investigations at higher doses and for longer exposure periods for possible oestrus induction and synchronization in higher mammals. Further favourable results could herald the possible patent of the catfish pituitary extract for either experimental or commercial use in mammals.

垂体通常产生和储存促性腺激素(GnH),这些激素负责动物的排卵和精子形成。然而,这种鱼类垂体提取物是否能在接受治疗的动物身上产生同样的效果,需要进一步阐明,作为其在动物身上实际应用的前奏。垂体通常产生和储存促性腺激素(GnH),这些激素负责动物的排卵和精子形成。然而,这种鱼类垂体提取物是否能在接受治疗的动物身上产生同样的效果,还需要阐明,作为其在动物身上实际应用的前奏。本研究的目的是研究非洲鲶鱼(Clarias gariepinus)垂体提取物对未成熟Wistar大鼠的雌激素诱导潜力。本研究的目的是研究非洲鲶鱼(Clarias gariepinus)垂体提取物对未成熟Wistar大鼠的雌激素诱导潜力。实验使用18只未成熟雌性Wistar大鼠和10只雄性鲶鱼,每组使用6只Wistar大白鼠,如下所示:A组接受人绒毛膜促性腺激素(hCG)治疗。B组仅接受生理盐水治疗,而C组则给予加里皮猴垂体提取物以诱导发情,每组间隔6小时进行两次治疗。明显表现出明显的发热迹象和子宫角水肿,生殖道重量、子宫宽度和长度显著增加(p<0.05)。然而,与其他测定的激素相比,hCG和C.gariepinus垂体提取物处理组中只有孕酮水平显著升高(p<0.05)。这些结果表明,C.gariepinus垂体提取物具有诱导Wistar大鼠发情的能力,因为它具有促性腺激素作用,这需要在更高剂量和更长暴露时间下进行进一步研究,以便在家养反刍动物中诱导和同步发情。没有一个
{"title":"Gonadotropic Activity of Pituitary Extract of African Catfish, <i>Clarias gariepinus</i>, in Mammals using Immature Wistar Rats as Models.","authors":"Simon Azubuike Ubah, Samson Eneojo Abalaka, Victory Clara Asibor, Ebenezer Kehinde Ogundana, Itodo Joy Iyojo, Oluwa Adikpe Agbonu, Philemon Kwinjoh Columbus, Kenneth Owoicho Abah, Christopher Ese Obudu, Oluwatobi Akefe Isaac, Prisca Adaoma Ezinwo","doi":"10.2174/1872208317666230313153832","DOIUrl":"10.2174/1872208317666230313153832","url":null,"abstract":"<p><strong>Background: </strong>The pituitary glands normally produce and stores gonadotropic hormones (GnH) that are responsible for ovulation and spermiation in animals. However, whether fish pituitary extracts can elicit same effects in treated animals need elucidation as a prelude to their practical usage in animals.</p><p><strong>Objectives: </strong>The aim of this study was to investigate the oestrus-inducing potential of the pituitary gland extract of the Africa Catfish (<i>Clarias gariepinus</i>) in immature Wistar rats.</p><p><strong>Methods: </strong>The experiment involved the use of 18 immature female Wistar rats and 10 male catfish brood stocks with the use of six Wistar rats per groups as follows: Group A had human chorionic gonadotropin (hCG) treatment. Group B had only normal saline treatment as the control whereas Group C had the <i>C. gariepinus</i> pituitary extract administration to induce oestrus with treatments occurring twice six hours apart in each group.</p><p><strong>Results: </strong>There was an obvious expression of visible signs of heat and the presence of uterine horn oedema with significant (<i>p</i> < 0.05) increase in reproductive tract weight and uterine width and length. However, only progesterone levels increased significantly (<i>p</i> < 0.05) in the hCG and the <i>C. gariepinus</i> pituitary extract treated groups compared to other assayed hormones.</p><p><strong>Conclusion: </strong>These results showed that <i>C. gariepinus</i> pituitary extract has the capacity to induce oestrus in Wistar rats because of its gonadotropic effects, which needs further investigations at higher doses and for longer exposure periods for possible oestrus induction and synchronization in higher mammals. Further favourable results could herald the possible patent of the catfish pituitary extract for either experimental or commercial use in mammals.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":"84-92"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48877651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meet the Editorial Board Member 与编辑委员会成员见面
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-12-01 DOI: 10.2174/187220831704230425220041
E. Jacob‐Lopes
{"title":"Meet the Editorial Board Member","authors":"E. Jacob‐Lopes","doi":"10.2174/187220831704230425220041","DOIUrl":"https://doi.org/10.2174/187220831704230425220041","url":null,"abstract":"","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68039109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Recent patents on biotechnology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1